Welcome to CSNpharm! For Research Use Only!
Home +1-708-781-1677

Bcr-Abl

Bcr-Abl

Cat. No. Product Name CAS No. Information
CSN16658 WP1130 856243-80-6 WP1130 is a selective small molecular deubiquitinase USP5 UCH-L1 USP9x USP14 and UCH37 inhibitor and a BcrAbl destruction pathway activator with an IC50 of 18 M for K562 cells
CSN22290 SNIPER(ABL)-062 2140260-89-3 SNIPERABL-062 is a potent SNIPER molecule that tethers BCR-ABL inhibitor to a ligand of IAP causes potent BCR-ABL degradation shows desirable binding affinities against ABL1 cIAP12 and XIAP IC5080-500 nM inhibits BCR-ABL-mediated signaling pathways and CML proliferation in cells expressing BCR-ABL
CSN18591 Radotinib   926037-48-1 Radotinib is a selective BCR-ABL1 inhibitor with IC50 of 34 nM also inhibits platelet-derived growth factor receptor PDGFR is used to treat cancers and Chronic Myeloid Leukemia
CSN22517 Target Protein-binding Moiety 8 910297-51-7 PROTAC Bcr-Abl-binding moiety 1 is a Dasatinib-based warhead ligand for conjugation reactions of PROTAC targeting on Bcr-Abl.
CSN12687 Ponatinib   943319-70-8 Ponatinib is a potent multi-target inhibitor of Abl PDGFR VEGFR2 FGFR1 and Src with IC50 of 037 nM 11 nM 15 nM 22 nM and 54 nM respectively
CSN12295 Nilotinib HCl H2O   923288-90-8 Nilotinib monohydrochloride is a Bcr-Abl inhibitor with IC50 30 nM
CSN11559 Nilotinib   641571-10-0 Nilotinib is a Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells
CSN12740 Lyn-IN-1 887650-05-7 Lyn-IN-1 is a potent and selective dual Bcr-AblLyn inhibitor with potential antineoplastic activity it is an orally bioavailable 2-phenylaminopyrimidine derivative
CSN17632 GZD824   1257628-77-5 GZD824 is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl WT and Bcr-Abl T315I with IC50 of 034 and 068 nM respectively
CSN18803 GZD824 Dimesylate 1421783-64-3 GZD824 dimesylate is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl WT and Bcr-Abl T315I with IC50 of 034 nM and 068 nM respectively
CSN15689 GNF-7 839706-07-9 GNF-7 inhibits Bcr-Abl WT and Bcr-Abl T315I with IC50 of 133 nM and 61 nM respectively
CSN12398 GNF-5   778277-15-9 GNF-5 is a selective non-ATP competitive inhibitor of Bcr-Abl with IC50 of 220 nM its an analogue of GNF-2 with improved pharmacokinetic properties
CSN13825 GNF-2 778270-11-4 GNF-2 is a highly selective non-ATP competitive inhibitor of oncogenic Bcr-Abl activity IC50 014 M
CSN17178 Flumatinib Mesylate 895519-91-2 Flumatinib mesylate a derivative of imatinib is a multi-kinase inhibitor with IC50 Values of 12 nM 3076 nM and 2662 nM for c-Abl PDGFR and c-Kit respectively
CSN18538 Flumatinib 895519-90-1 Flumatinib is a multi-kinase inhibitor with IC50 Values of 12 nM 3076 nM and 2662 nM for c-Abl PDGFR and c-Kit respectively
CSN16096 DPH 484049-04-9 DPH is a potent cell permeable c-Abl activator which displays potent enzymatic and cellular activity in stimulating c-Abl activation
CSN13733 DCC-2036 1020172-07-9 DCC-2036 is a conformational control Bcr-Abl inhibitor for Abl1 WT and Abl1 T315I with IC50 of 08 nM and 4 nM also inhibits SRC LYN FGR HCK KDR FLT3 and Tie-2
CSN12769 Dasatinib Monohydrate   863127-77-9 Dasatinib is a potent and multi-targeted inhibitor that targets Abl Src and c-Kit with IC50 of 1 nM 08 nM and 79 nM respectively
CSN16497 Dasatinib   302962-49-8 Dasatinib is a potent and dual Abl/ Src inhibitor IC50 of < 1 nM/0.8 nM respectively and also inhibits c-Kit (WT)/c-Kit (D816V) with IC50 of 79 nM/37 nM.
CSN18475 Dasatinib HCl 854001-07-3 Dasatinib hydrochloride is a potent and dual Abl Src inhibitor IC50 of 1 nM08 nM respectively and also inhibits c-Kit WTc-Kit D816V with IC50 of 79 nM37 nM
CSN21248 BCR-ABL-IN-1 188260-50-6 BCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase with a pIC50 of 646 and may be used in the research of chronic myelogenous leukemia
CSN19269 Bafetinib   859212-16-1 Bafetinib is a potent and selective dual Bcr-AblLyn inhibitor with IC50 of 5.8 nM19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit.
CSN18872 Asciminib 1492952-76-7 Asciminib is a potent and selective allosteric Bcr-Abl inhibitor and inhibits BaF3 cells grown with an IC50 of 025 nM
CSN23049 PPY A 875634-01-8
<< PREV 1 NEXT >>